GlassScriptPhysician profile
Michael S Hamman
NPI 1538346911
$4,363.42
in general payments reported to CMS, 2019-2025
25 companies · $1,132 in 2025
The $1,132 reported for 2025 was more than what 77% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $21.02 · 2021: $163 · 2022: $390 · 2023: $1,218 · 2024: $1,218 · 2025: $1,132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,568.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $625.82 | 2019-2025 | |
| Lilly USA, LLC | $531.46 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $431.26 | 2023-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $403.01 | 2020-2025 | Ilumya, Blu-U, Odomzo |
| Genzyme Corporation | $396.67 | 2019-2025 | |
| Pfizer INC. | $384.37 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $261.60 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $245.47 | 2022-2025 | Libtayo, Dupixent |
| Ucb, INC. | $234.71 | 2021-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $137.61 | 2023-2024 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $128.08 | 2023-2025 | Zoryve |
| Janssen Biotech, INC. | $100.93 | 2023-2025 | Tremfya |
| Leo Pharma INC. | $90.18 | 2019-2025 | Adbry |
| Almirall LLC | $61.90 | 2021-2025 | Klisyri |
| Amgen INC. | $49.13 | 2024-2025 | Otezla, Otezla |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $46.40 | 2019-2022 | |
| Galderma Laboratories, L.P. | $45.26 | 2025 | Aklief |
| Biofrontera INC. | $41.54 | 2022-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Organogenesis INC. | $26.58 | 2024 | |
| Celgene Corporation | $24.21 | 2019 | |
| Cipher Pharmaceuticals US LLC | $20.36 | 2025 | Natroba, Spinosad |
| Genentech USA, INC. | $20.07 | 2023 | Erivedge |
| Helsinn Therapeutics (U.S.), INC. | $19.25 | 2024 | Valchlor |
| Dusa Pharmaceuticals, INC. | $19.11 | 2019 | |
| Merck Sharp & Dohme LLC | $18.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hamman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.